Abstract Title:

Effects of phosphatidylserine in Alzheimer's disease.

Abstract Source:

Psychopharmacol Bull. 1992;28(1):61-6. PMID: 1609044

Abstract Author(s):

T Crook, W Petrie, C Wells, D C Massari

Article Affiliation:

Memory Assessment Clinics, Inc., Bethesda, MD 20814.


We studied 51 patients meeting clinical criteria for probable Alzheimer's disease (AD). Patients were treated for 12 weeks with a formulation of bovine cortex phosphatidylserine (BC-PS; 100 mg t.i.d.) or placebo, and those treated with the drug improved on several cognitive measures relative to those administered placebo. Differences between treatment groups were most apparent among patients with less severe cognitive impairment. Results suggest that phosphatidylserine may be a promising candidate for study in the early stages of AD.

Study Type : Human Study

Print Options

Key Research Topics

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2024 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.